Beware! 2DG COVID medicine will not see the daylight before June

The generic drugmaker released a statement on social media saying the anti-COVID remedy oral drug 2DG has not yet been launched into the market. Here, we advise our readers to remain vigilant and refrain themselves from falling into the trap of black marketers who lure them by offering the 2DG drug in exchange for a hefty amount. We request you to share this article with your friends and relative so as to alert your surroundings.

New Delhi: Generic drugmaker Dr Reddy's Laboratories, which has developed the drug 2DG as a potential game-changer in the fight against COVID-19, has warned the public against the spurious and illegal products in the name of 2DG. Clinical trial registry data suggest that phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August.

The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients.

The pharmaceutical company that is all set to produce the drug for hospitals and the markets on Thursday (May 20), released a statement on Twitter regarding the 2DG medicine. It read: 

#2DG. For all queries related to 2DG, please write to 2DG@drreddys.com.#DrReddys pic.twitter.com/FgGqrnfuEn — Dr. Reddy's (@drreddys) May 19, 2021

While 2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally, trials to use it as a COVID-19 drug are apparently being done in India only and incidentally, a strong case for its therapeutic use against the novel coronavirus was made in a study paper last year.

The Drugs Controller General India (DCGI) had granted permission in May last year to Dr Reddy's Laboratories to conduct a clinical trial of 2-DG for 'acute treatment of moderate to severe COVID-19 patients'.

Interestingly, Dr Reddy's became the secondary sponsor after phase-2 trials and the DRDO's Institute of Nuclear Medicine and Allied Sciences became the primary sponsor and main source for material or monetary support during the phase-3 trial.

The phase II clinical trials were conducted at 12 sites across India, including at private and government hospitals. The trials were conducted over a three-month period between June-September 2020, for which a total of 110 COVID-19 patients aged 18-65 years were enrolled.

Those with COVID-19 symptoms like fever, cough, difficulty in breathing, fatigue, body ache, headache, diarrhoea, nasal congestion took part in phase-2 clinical trials. The drug was found to be safe in COVID-19 patients and showed significant improvement in their recovery.